Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Health-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidity.
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Decreased systemic IL-7 and soluble IL-7Rα in multiple sclerosis patients.
Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study.
Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use.
Origin, fate and dynamics of macrophages at central nervous system interfaces.
[Th17-mediated relapsing-remitting multiple sclerosis is nonresponsive to interferon-β1b].
Novel MS Drugs Advance
Gene Expression Profiles of Autophagy-Related Genes in Multiple Sclerosis.
Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients with Relapsing-Remitting Multiple Sclerosis.
Influence of infection on exacerbations of multiple sclerosis.
Association between beta-interferon exposure and hospital events in multiple sclerosis.
Checklist for reporting and reviewing studies of experimental animal models of multiple sclerosis and related disorders.
Dimethyl fumarate for multiple sclerosis.
Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?
Validation of the Brazilian version of the neurological fatigue index for multiple sclerosis.
Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway.
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
Impact of Disease-Modifying Therapies on the Survival of Patients with Multiple Sclerosis in Taiwan, 1997-2008.
White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.
Therapy Optimization in Multiple Sclerosis: A cohort study of therapy adherence and risk of relapse.
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Genes associated with T helper 17 cell differentiation and function.
Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada) in Multiple Sclerosis
Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study.

Pages